Soleno Operating Cycle from 2010 to 2026

SLNO Stock  USD 39.07  0.98  2.57%   
Soleno Therapeutics Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to grow to 1,970 this year. During the period from 2010 to 2026, Soleno Therapeutics Operating Cycle quarterly data regression pattern had sample variance of  886,748 and median of  1,970. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
1.9 K
Current Value
K
Quarterly Volatility
941.67312301
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 5.7 M or Selling General Administrative of 17 M, as well as many indicators such as Price To Sales Ratio of 14.13, Dividend Yield of 0.0 or PTB Ratio of 7.6. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Soleno Stock
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
Evaluating Soleno Therapeutics's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Soleno Therapeutics's fundamental strength.

Latest Soleno Therapeutics' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Soleno Therapeutics over the last few years. It is Soleno Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Soleno Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Soleno Operating Cycle Regression Statistics

Arithmetic Mean1,308
Geometric Mean519.08
Coefficient Of Variation72.02
Mean Deviation876.73
Median1,970
Standard Deviation941.67
Sample Variance886,748
Range2.1K
R-Value0.85
Mean Square Error261,427
R-Squared0.72
Significance0.000015
Slope158.63
Total Sum of Squares14.2M

Soleno Operating Cycle History

2026 1970.42
2025 1876.59
2017 2085.1
2016 193.25
2014 717.29

About Soleno Therapeutics Financial Statements

Soleno Therapeutics investors utilize fundamental indicators, such as Operating Cycle, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle1.9 KK

Pair Trading with Soleno Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Soleno Stock

  0.72OSE OSE Pharma SAPairCorr

Moving against Soleno Stock

  0.76VALN Valneva SE ADRPairCorr
  0.73GXEA Galapagos NVPairCorr
  0.738VP1 AVRICORE HEALTH INCPairCorr
  0.66EQ EquilliumPairCorr
  0.63DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.75)
Revenue Per Share
3.747
Return On Assets
0.0209
Return On Equity
0.0601
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value - what Soleno Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.